Information  X 
Enter a valid email address

Immunodiagnostic Sys (IDH)

  Print      Mail a friend

Thursday 11 July, 2019

Immunodiagnostic Sys

Director/PDMR Shareholding

RNS Number : 2753F
Immunodiagnostic Systems Hldgs PLC
11 July 2019
 

Immunodiagnostic Systems Holdings PLC 

Director/PDMR Dealing

11 July 2019 

Immunodiagnostic Systems Holdings PLC ("IDS") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that it has granted the following options to persons discharging managerial responsibilities to acquire ordinary shares of 2p in the capital of the Company under the Company's Co-Investment Executive Option Scheme.  


Position

Date of Grant

Number of Options

Exercise Price

Paul Martin

Finance Director

28 March 2017

30,000

£1.320

28 March 2017

9,000

£2.775

29 March 2018

6,000

£2.200

29 March 2018

6,300

£2.900

28 March 2019

6,750

£1.840

Jaap Stuut

CEO

29 March 2018

7,500

£2.200

28 March 2019

7,500

£1.900

Nicola Mitton

HR Director

29 March 2018

3,000

£2.200

 

Under this scheme, participants who purchase ordinary shares in the Company ("Co-Investment Shares") are entitled to three share options for each Co-Investment Share they purchase.   The exercise price for the options is set at the price the participant paid for each Co-Investment Share. 

The options are subject to the satisfaction of performance conditions and vest after a period of 3 years. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014. 

For further information:

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Paul Martin, Group Finance Director




Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel


Oliver Jackson


 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.         

Details of the person discharging managerial responsibilities / person closely associated

a.      

Name

1.   Paul Martin

2.   Jaap Stuut

3.   Nicola Mitton

2.         

Reason for the notification

a.         

Position/
status

1.   Group Finance Director

2.   Chief Executive Officer

3.   HR Director

a.         

Initial notification

/Amendment

Initial

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.         

Name

Immunodiagnostic Systems Holdings plc

b.         

LEI

213800HZMYTD4NGF4L78

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the Financial instrument,

Type of instrument

Identification code

Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc

 

Ordinary shares

GB00B01YZ052

b.         

Nature of the transaction

Grant of options

c.         

Price(s) and volume(s)


Date of Grant

Number of Options

Exercise Price

Paul Martin

28 March 2017

30,000

£1.320

28 March 2017

9,000

£2.775

29 March 2018

6,000

£2.200

29 March 2018

6,300

£2.900

28 March 2019

6,750

£1.840

Jaap Stuut

29 March 2018

7,500

£2.200

28 March 2019

7,500

£1.900

Nicola Mitton

29 March 2018

3,000

£2.200

 

 

d.         

Aggregated information

N/A

e.         

Date of the transaction

see table above in section c

f.         

Place of the transaction

Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBXGDRSBBBGCB

a d v e r t i s e m e n t